Abstract:A211 Cervical cancer caused by the high-risk strains of Human papillomavirus (HPV) and levels of the tumor suppressor protein p53 were found to be unusually low due to the presence of E6 and E7 proteins encoded by the oncogenic HPV. Expression of Human papillomavirus E6 and E7 is necessary to maintain the transformed state of cervical cancer cells. The E6 promoted degradation of p53 involves the ubiquitin-proteasome pathway and represents a major mechanism, by which virus transforms the host cells. The ability of E6 to target multiple cellular tumor suppressor proteins, notably p53 and several PDZ family numbers enforces the necessity for the development of potential therapeutic targets for the rapid proteolytic degradation. Initial studies with only licensed proteasome inhibitor, Bortezomib (Velcade/PS-341) indicated a therapeutic index in HPV transformed as compared to HPV negative cervical cancer lines, and immortalized or primary keratinocytes, suggesting the promise of this approach. Indeed, Bortezomib (1mg/kg, twice weekly) significantly retarded the growth of the HPV18-transformed HeLa cell xenograft. However, although Bortezomib restored the expression of wild type p53 in several cervical cancer cell lines, it had no effect upon expression of several important PDZ tumor suppressors, hDlg, hScribble, hMAGI family. Therefore, we began an effort to develop potent second generation proteasome inhibitors that prevent E6-mediated degradation of more of its target cellular proteins based on our previously published compound 3,5-bis-(4-boronic acid-benzylidene)-1-methyl-piperidin-4-one(AM114). Through a series of modifications of this family, including attachment of various peptides to target different proteolytic activities of the proteasome, we have explored the chemical space surrounding this compound to develop comprehensive structure activity relationships. The new lead compound, AMV-146 exhibits a Ki of ~2µM for in vitro killing of HeLa and CaSki cells (HPV18 and HPV16 transformed cells respectively). AMV-146 restored wild type p53 expression in HeLa, and HPV16-transformed SiHa and CaSki cells, but had no effect upon p53 expression in HPV-negative HT3 cells and the spontaneously immortalized keratinocyte line HaCaT. Two related compounds, KI-VI-58 and KI-VI-55 exhibit Ki of ~2µM and 2.5µM against both HeLa and CaSki cells.

Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.

In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells.

Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Oncolytic Adenovirus Zd55-Trail As A Therapy Against Cervical Cancer

Synergistic Induction of Apoptosis in HeLa Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitor SAHA.

In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line.

The Antitumor Efficiency of Zinc Finger Nuclease Combined with Cisplatin and Trichostatin A in Cervical Cancer Cells

Targeting of Histone Deacetylases to Reactivate Tumour Suppressor Genes and Its Therapeutic Potential in a Human Cervical Cancer Xenograft Model

The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo

Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout

Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells

HDAC As a Therapeutic Target for Treatment of Endometrial Cancers

EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer

Suberoyl Bis-Hydroxamic Acid Enhances Cytotoxicity Induced by Proteasome Inhibitors in Breast Cancer Cells.

HDAC Inhibitors Augmented Cell Migration and Metastasis Through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy

Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A

Synergistic Efficacy In Human Ovarian Cancer Cells By Histone Deacetylase Inhibitor Tsa And Proteasome Inhibitor Ps-341

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for human uterine sarcoma cells.

Structure-Based Discovery of Potential HPV E6 and EBNA1 Inhibitors: Implications for Cervical Cancer Treatment

Antitumor Activity of the Novel HDAC Inhibitor CUDC-101 Combined with Gemcitabine in Pancreatic Cancer

Candidate Proteasome Inhibitors That Prevent E6 Mediated P53 Degradation and Selectively Kill Hpv Plus Cervical Cancer Cells

Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer